BioNexus Gene Lab Corp

For the period ended Dec 31, 2025. Filed Apr 14, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Apr 14, 2026

BGLC$0.82-8.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 15. Exhibits, Financial Statement Schedules

EXHIBIT INDEX

ExhibitNumber	Description
1.1**	Form of Underwriting Agreement
3.1**	Articles of Incorporation of the Registrant, as currently in effect
3.2**	Bylaws of the Registrant, as currently in effect
3.3**	Certificate of Amendment filed with the Secretary of the State of Wyoming on June 7, 2017
3.4**	Certificate of Amendment filed with the Secretary of the State of Wyoming on March 29, 2023

3.5**	Certificate of Amendment filed with the Secretary of the State of Wyoming on June 5, 2023
3.6**	Articles of Amendment filed with the Wyoming Secretary of State on February 11, 2025.
3.7**	Articles of Amendment filed with the Wyoming Secretary of State on April 1, 2025.
4.1**	Registrant’s Specimen Certificate for Common Stock
4.2**	Form of Representative’s Warrant
10.1**	Share Exchange Agreement between BioNexus and Chemrex
10.2**	Employment Agreement with Su-Leng Tan Lee
10.3**	Director Offer Letter by and between the Registrant and Su-Leng Tan Lee
10.4**	Director Offer Letter by and between the Registrant and Muhammad Azrul bin Abdul Hamid
10.5**	Director Offer Letter by and between the Registrant and Jook Yuen Low
10.6**	Director Offer Letter by and between the Registrant and Chee Keong Yap
10.7	The Service Contract between the Company and Ms. Chong Set Fui (Angeline)
10.8	Equity Distribution Agreement, dated November 7, 2025, between BioNexus Gene Lab Corp. and Maxim Group LLC (incorporated by reference to Exhibit 1.1 to the Registration Statement on Form S-3 (File No. 333-291379) filed with the SEC on November 7, 2025).

10.9	Share Subscription and Shareholders’ Agreement, dated November 12, 2025, by and among Fidelion Diagnostics Pte. Ltd., BioNexus Gene Lab Corp., and the other parties thereto.
10.10	Equity Purchase Agreement, dated November 28, 2025, by and between BioNexus Gene Lab Corp. and ARC Group International Ltd.
10.11	Exclusive Intellectual Property License Agreement (Southeast Asia), dated November 28, 2025, by and between BioNexus Gene Lab Corp. and Fidelion Diagnostics Pte. Ltd.
19+	Code of Business Conduct and Ethics
21.1+	List of Subsidiaries of the Registrant
31.1	Certification of the Company’s Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002+
31.2	Certification of the Company’s Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002+
32.1	Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+
32.2	Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+
97+	Policy Relating to Recovery of Erroneously Awarded Compensation
99.2**	Audit Committee Charter
99.3**	Compensation Committee Charter
99.4**	Nomination Committee Charter
101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

+	Filed herewith.
**	Previously filed.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.